Gertjan H J Wagenvoort1, Elisabeth A M Sanders2, Bart J Vlaminckx3, Karin E Elberse4, Hester E de Melker4, Arie van der Ende5, Mirjam J Knol4. 1. Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: wagenvoort@gmail.com. 2. Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands; Department of Immunology and Infectious diseases, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, The Netherlands. 3. Department of Medical Microbiology and Immunology, St. Antonius Hospital, Nieuwegein, The Netherlands. 4. Centre for Infectious Disease Control Netherlands (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. 5. Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) in the Dutch national immunization program for infants led to a shift from vaccine to non-vaccine serotypes in invasive pneumococcal disease (IPD) in all age groups. We studied the impact of the serotype shift on clinical syndromes and outcomes. METHODS: Pneumococcal isolates from hospitalized IPD patients obtained from nine sentinel microbiology laboratories, covering 25% of the Dutch population, were serotyped. Clinical syndromes, outcomes and patient characteristics in the post-PCV7 (2008-2012) period were compared with the pre-PCV7 period (2004-2006). Serotype specific propensity of the association with empyema, meningitis and death was calculated. RESULTS: Invasive pneumonia incidence significantly decreased in children <5 years and elderly ≥65 years, but increased in 5-64 years old from 4.92 to 5.58 cases/100.000/year (RR 1.13 95% CI 0.99-1.29). Empyema incidence significantly increased in elderly 65 years and older from 0.61 to 2.60 cases/100.000/year (RR 4.28 95% CI 1.97-9.33), mainly due to serotype 1. The incidence of meningitis only declined significantly in children <5 years. IPD case-fatality decreased in children <5 years from 5% to 3%, in 5-64 years old from 9% to 7% and in elderly ≥65 years significantly from 22% to 17%, due to lower case-fatality rates for most emerging non-PCV7 serotypes. CONCLUSIONS: An increase in empyema incidence was observed in persons ≥65 years old in the post-PCV7 era, mainly due to the emergence of serotype 1, although overall IPD case-fatality decreased. Extended conjugate vaccines that target serotype 1 or serotypes with high case-fatality may offer further reduction of pneumococcal disease burden.
BACKGROUND: Implementation of 7-valent pneumococcal conjugate vaccine (PCV7) in the Dutch national immunization program for infants led to a shift from vaccine to non-vaccine serotypes in invasive pneumococcal disease (IPD) in all age groups. We studied the impact of the serotype shift on clinical syndromes and outcomes. METHODS:Pneumococcal isolates from hospitalized IPD patients obtained from nine sentinel microbiology laboratories, covering 25% of the Dutch population, were serotyped. Clinical syndromes, outcomes and patient characteristics in the post-PCV7 (2008-2012) period were compared with the pre-PCV7 period (2004-2006). Serotype specific propensity of the association with empyema, meningitis and death was calculated. RESULTS: Invasive pneumonia incidence significantly decreased in children <5 years and elderly ≥65 years, but increased in 5-64 years old from 4.92 to 5.58 cases/100.000/year (RR 1.13 95% CI 0.99-1.29). Empyema incidence significantly increased in elderly 65 years and older from 0.61 to 2.60 cases/100.000/year (RR 4.28 95% CI 1.97-9.33), mainly due to serotype 1. The incidence of meningitis only declined significantly in children <5 years. IPD case-fatality decreased in children <5 years from 5% to 3%, in 5-64 years old from 9% to 7% and in elderly ≥65 years significantly from 22% to 17%, due to lower case-fatality rates for most emerging non-PCV7 serotypes. CONCLUSIONS: An increase in empyema incidence was observed in persons ≥65 years old in the post-PCV7 era, mainly due to the emergence of serotype 1, although overall IPD case-fatality decreased. Extended conjugate vaccines that target serotype 1 or serotypes with high case-fatality may offer further reduction of pneumococcal disease burden.
Authors: Melina Messaoudi; Milen Milenkov; Werner C Albrich; Mark P G van der Linden; Thomas Bénet; Monidarin Chou; Mariam Sylla; Patricia Barreto Costa; Nathalie Richard; Keith P Klugman; Hubert P Endtz; Gláucia Paranhos-Baccalà; Jean-Noël Telles Journal: PLoS One Date: 2016-03-17 Impact factor: 3.240
Authors: Anne L Wyllie; Lidewij W Rümke; Kayleigh Arp; Astrid A T M Bosch; Jacob P Bruin; Nynke Y Rots; Alienke J Wijmenga-Monsuur; Elisabeth A M Sanders; Krzysztof Trzciński Journal: Sci Rep Date: 2016-10-07 Impact factor: 4.379
Authors: Gertjan H J Wagenvoort; Elisabeth A M Sanders; Bart J Vlaminckx; Hester E de Melker; Arie van der Ende; Mirjam J Knol Journal: Euro Surveill Date: 2017-03-09
Authors: Dominic Thorrington; Leo van Rossum; Mirjam Knol; Hester de Melker; Hans Rümke; Eelko Hak; Albert Jan van Hoek Journal: PLoS One Date: 2018-02-09 Impact factor: 3.240
Authors: Anne L Wyllie; Joshua L Warren; Gili Regev-Yochay; Noga Givon-Lavi; Ron Dagan; Daniel M Weinberger Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 9.079
Authors: Wilke Hendriks; Hendriek Boshuizen; Arnold Dekkers; Mirjam Knol; Ge A Donker; Arie van der Ende; Hester Korthals Altes Journal: Influenza Other Respir Viruses Date: 2017-01-03 Impact factor: 4.380
Authors: Marloes Vissers; Alienke J Wijmenga-Monsuur; Mirjam J Knol; Paul Badoux; Marlies A van Houten; Arie van der Ende; Elisabeth A M Sanders; Nynke Y Rots Journal: PLoS One Date: 2018-03-30 Impact factor: 3.240